A practical reference on storage stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-26. Anything still debated is marked as such rather than presented as settled.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
==== Spinal cord ==== In spinal cord, KOR is expressed in the substantia gelatinosa and superficial laminae of the dorsal horn, where they modulate thermal nociception and chemical viscelar pain. They are concentrated in the upper laminae of the dorsal horn (laminae I–III) and within the posterolateral tract. The highest density was localized within the inner segment of lamina II, forming a dense band immediately dorsal to lamina III. 53% of KOR binding sites in the superficial dorsal horn (laminae I–II) are localized presynaptically on primary afferent terminals, with the remainder distributed postsynaptically.
Later that month, during the final days before the United States fell off the "fiscal cliff", Biden's relationship with McConnell again proved important as the two negotiated a deal that led to the American Taxpayer Relief Act of 2012 being passed at the start of 2013.
== Background == By the mid-1790s, Humboldt had devoted himself wholly to scientific investigations. Despite being offered a promotion and an increase in pay, he resigned his position as a mining official in the Prussian civil service in order to embark on a journey that would “advance him scientifically.” To the Minister of Mines in Berlin Humboldt declared: "I am considering a complete change in my mode of life, and I intend to withdraw from any official position with the state." His health, he claimed, had suffered. All he had wanted was to prepare himself for a scientific expedition by a practical employment in the mines. "As I have a deep conviction that such an expedition is highly important for increasing our knowledge of geology and physical science, I am exceedingly eager to devote my energies immediately to this end. After his mother's death in 1796, Humboldt inherited the financial means to pursue independent explorations. He decided to go to Italy, where he wanted to spend a year to a year and a half researching volcanoes. From there, he wanted to travel via Paris to England, where he would board a ship to the West Indies. However, the political instability caused by Napoleon's Italian campaign in 1797 forced Humboldt to cancel his plans. In May 1798, Humboldt traveled to Paris, where he met the botanist Aimé Bonpland. After their attempt to travel to Egypt had once again failed due to Napoleon and his campaign there, the two decided to go to Madrid in December 1798.
Different antibiotics have been tried both alone and together, but none are completely effective at eliminating the disease. The combination of minocycline and streptomycin is thought to be useful, but it is often unaffordable. Tetracycline can be a less expensive substitute for minocycline, but it also lowers the effect of the treatment. Long term antibiotics can be given but usually results in a relapse. Spaying and neutering can be effective, and frequent blood tests are recommended to monitor progress. Dogs in kennels that are affected by B. canis are usually euthanized for the protection of other dogs and the humans caring for them. B. canis is relatively easy to prevent in dogs. Any dog that will be used for breeding or has the capability to breed should be serologically tested before mating. All dogs new dogs being introduced to a kennel should be examined for signs of the disease and quarantined before being exposed to other dogs. There are currently no approved serologic tests approved for testing for B. canis in humans. Treatment for human Brucellosis usually includes combination antibiotic treatment for at least 6 weeks. Recovery can range from a few weeks to months, however brucellosis rarely causes death in humans (estimated no more than 2% die from infection).
the act was of such a lewd character as to outrage public decency; this element constitutes the nature of the act, which has to be proved before the offence can be established, and the act took place in a public place and must have been capable of being seen by two or more persons who were actually present, even if they did not actually see it. The mens rea of this offence can be satisfied if the defendant intentionally does an act which outrages public decency, regardless of one's state of mind. Judge Peter Rook QC and Robert Ward suggest that obiter dicta in cases such as R v Thallman (1863) 9 Cox CC 388 indicate that the requirement of a "public place" may be falling out of favour, due to its vagueness and redundancy to the requirement for two potential witnesses. In R v Hamilton [2007] EWCA Crim 2062 an act of upskirting in public went undetected until a police search discovered indecent images. It was held that it was immaterial whether a person had actually seen the act, provided it was capable of being seen by at least two persons. Previous cases had all been seen, but this was held to be a matter of evidence, not an element of the offence.
Sources: en.wikipedia.org
Oganesson is a synthetic chemical element; it has symbol Og and atomic number 118. It was first synthesized in 2002 at the Joint Institute for Nuclear Research (JINR) in Dubna, near Moscow, Russia, by a joint team of Russian and American scientists. In December 2015, it was recognized as one of four new elements by the Joint Working Party of the international scientific bodies IUPAC and IUPAP. It was formally named on 28 November 2016. The name honors the nuclear physicist Yuri Oganessian, who played a leading role in the discovery of the heaviest elements in the periodic table. Oganesson has the highest atomic number and highest atomic mass of all known elements. On the periodic table of the elements it is a p-block element, a member of group 18, and the last member of period 7. Its only known isotope, oganesson-294, is highly radioactive, with a half-life of 0.7 ms. This half-life is too short for chemical studies. Because of relativistic effects, theoretical studies predict that it would be a solid at room temperature, and significantly reactive, unlike the other members of group 18 (the noble gases).
Phenelzine, sold under the brand name Nardil among others, is a non-selective and irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine family which is primarily used as an antidepressant and anxiolytic to treat depression and anxiety. Along with tranylcypromine and isocarboxazid, phenelzine is one of the few non-selective and irreversible MAOIs still in widespread clinical use.
Texts on Wikisource: Chisholm, Hugh, ed. (1911). "Amines" . Encyclopædia Britannica (11th ed.). Cambridge University Press. Synthesis of amines Factsheet, amines in food Archived 19 February 2018 at the Wayback Machine
==== Assessments ==== Heseltine was not popular with his ministerial peers at this time. A story was told of how ministers had volunteered him to be the one "taken hostage by terrorists" in a mooted training exercise. Nonetheless, Heseltine emerged from the Heath government with an enhanced reputation. He had avoided the worst crises of that government: the two miners' strikes, incomes policy, industrial relations policy and Northern Ireland, as well as any direct involvement in British entry into the EEC. Heseltine's career under Heath's ministry saw him associated with local government reorganisation, prestige projects, Europe and state aid to industries, themes which would recur throughout his career. He had attained a higher public profile than many Cabinet ministers, and by 1974 he was being seriously tipped as a future prime minister. Heseltine was promoted to the Shadow Cabinet in June 1974 as Industry spokesman. If the Conservatives had won either of the general elections in 1974 (February or October) he would almost certainly have joined the Cabinet. He was shadowing Tony Benn, who planned a major expansion of public ownership through the National Enterprise Board. In the summer of 1974, Heseltine put together a team of over 20 Conservative MPs, each a specialist in a particular industry, to campaign against Benn's plans.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.